Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sample sizes for bioequivalence studies.

C M Metzler1

  • 1Upjohn Company, Kalamazoo, Michigan 49001.

Statistics in Medicine
|June 1, 1991
PubMed
Summary
This summary is machine-generated.

This study presents curves to help manufacturers determine the appropriate sample size for bioequivalence studies. These curves aid in balancing the risk of falsely concluding non-bioequivalence with study efficiency.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Getting a slant on syncope.

Nursing·1999
Same author

Refinement and comparisons of the crystal structures of pig cytosolic aspartate aminotransferase and its complex with 2-methylaspartate.

The Journal of biological chemistry·1997
Same author

NMR studies of 1H resonances in the 10-18-ppm range for cytosolic aspartate aminotransferase.

The Journal of biological chemistry·1994
Same author

NMR studies of 1H resonances in the 10-18-ppm range for aspartate aminotransferase from Escherichia coli.

The Journal of biological chemistry·1994
Same author

NMR spectroscopy of exchangeable protons of glucoamylase and of complexes with inhibitors in the 9-15-ppm range.

European journal of biochemistry·1994
Same author

Starch-binding domain of Aspergillus glucoamylase-I. Interaction with beta-cyclodextrin and maltoheptaose.

Annals of the New York Academy of Sciences·1994
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
See all related articles

Area of Science:

  • Pharmacokinetics and Pharmaceutical Sciences
  • Biostatistics
  • Regulatory Science

Background:

  • Statistical decision rules are crucial for determining bioequivalence between test and reference drug formulations.
  • The confidence interval (CI) approach is widely accepted by regulatory bodies like the U.S. Food and Drug Administration (FDA).
  • Regulatory agencies focus on alpha levels for protection, while manufacturers are concerned with sample size and the risk of false non-bioequivalence.

Purpose of the Study:

  • To provide manufacturers with tools for selecting optimal sample sizes in bioequivalence studies.
  • To illustrate the relationship between sample size, error levels, and the probability of falsely rejecting bioequivalence.

Main Methods:

  • Computation of probability curves for rejecting bioequivalence.

Related Experiment Videos

  • Analysis across varying coefficients of variation (10%, 20%, 30%).
  • Evaluation for relative bioavailability ranges (70%-130%) and protection levels (90%, 95%).

    • Main Results:

    • Generated curves demonstrate the probability of incorrectly concluding non-bioequivalence.
    • These curves are specific to different error coefficients of variation and bioavailability levels.
    • The results facilitate informed sample size selection based on desired protection levels.

    Conclusions:

    • The presented curves are valuable for manufacturers in designing bioequivalence studies.
    • They enable efficient sample size determination, balancing statistical rigor with practical considerations.
    • This aids in ensuring reliable bioequivalence assessments while optimizing study resources.